The Effect of Recombinant Tissue Plasminogen Activator on the Intracerebral Hematomas in Experimental Cat Models

ABSTRACT

OBJECTIVE: Recent clinical studies have demonstrated that intracisternal administration of recombinant tissue plasminogen activator(rt-PA) can facilitate the normal clearing of blood from the subarachnoid space. Urokinase, a first generation fibrinolytic agent, has been used to liquify such clots with some success. Therefore, recombinant tissue plasminogen activator, a second generation fibrinolytic drug that may be safer and more effective, is studied to evaluate its dosage to lyse clots in vitro and reactivity in the brain parenchyme. METHODS: Intracerebral hematomas were created by stereotactically injecting 2ml of clotted autogenous blood into the brain parenchyme of total 28 anesthetized adult cats (weighting 3.8 to 4.1kg). The control animals (group A) received 1ml of normal saline injected into the clots and the experimental animals received each 0.1mg of rt-PA (group B), 0.5mg of rt-PA (group C) and 1mg of rt-PA (group D) at 6 hours after the clot injection. RESULTS: 1. The amount of remained clots after lysing the hematomas were as follows 1.80+/-0.17ml in group A, 1.65+/-0.23ml in group B, 0.61+/-0.37ml in group C and 0.52+/-0.34 in group D. The result indicated that hematomas in rt-PA treated groups (C & D) were lysed better than the control group. 2. At least 0.5mg of rt-PA should be required for the lysis of 2ml of hematomas. 3. Light microscopic examination revealed no histological evidence of hemorrhage in tissue sections from each brain. CONCLUSION: Recombinant tissue plasminogen activator may be safely and effectively employed for the lysis of intracerebral hematomas in animal model.